Sunovion gains Elevation in respiratory sector with promising nebulised COPD contender
This article was originally published in Scrip
Dainippon Sumitomo Pharma's Sunovion Pharmaceuticals unit will pay $100 million upfront and up to $330 million in milestone payments to acquire Elevation Pharmaceuticals, based on positive Phase IIb data in moderate to severe chronic obstructive pulmonary disease (COPD) for the private San Diego-based company's nebulised long-acting muscarinic antagonist (LAMA) EP-101.
You may also be interested in...
Private Company Edition: Omega raised $438m for its sixth life science fund, while Perceptive and the accelerator Xontogeny partnered on a new $210m venture capital fund. In VC deals, Zentalis and Black Diamond raised $85m each.
The Gilead subsidiary presented updated data at ASH for its first CD19-targeting CAR-T Yescarta and pivotal results for KTE-X19, which it plans to submit for US FDA approval in mantle cell lymphoma this year.
In its first ASH since acquiring Celgene and with competitors coming, Bristol presented pivotal results for liso-cel (JCAR017) that support a year-end US FDA submission as bb2121 nears a first-half of 2020 filing.